Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Interrupted treatment leads to poor outcomes in PCI

15 Dec 2019

The interruption of thienopyridine treatment within 6 months of percutaneous coronary intervention (PCI) is common and may lead to greater risks of major adverse cardiac and cerebrovascular events (MACCE), a recent study has found.

Researchers enrolled 23,002 participants from the dual antiplatelet therapy (DAPT) study, which assessed treatment interruptions >24 hours within 6 months after PCI. The incidence of MACCE, as well as of other complications, was compared between patients grouped according to interruption status.

A total of 1,173 patients (5.1 percent; mean age, 62.4±10.7 years; 30.4 percent female) reported treatment interruptions during the 6-month window; the remaining did not (n=21,829; mean age, 62.0±10.6 years; 27.6 percent female).

MACCEs occurred at an incidence rate of 4.4 percent. Myocardial infarction was reported in 2.8 percent, stroke in 0.7 percent and death in 4.4 percent.

Patients with thienopyridine interruptions experienced significantly greater MACCE incidence rates (6.1 percent vs 4.3 percent; p=0.005), such that treatment interruptions emerged as a significant predictor of the outcome (odds ratio [OR], 1.3, 95 percent confidence interval, 1.0–1.7; p=0.037). Analyses were adjusted for comorbidities, baseline PCI characteristics, DAPT score and stent type.

Survival was likewise worse in patients who had treatment interruptions (2.2 percent vs 1.4 percent; p=0.02), as was moderate or severe bleeding, though only with borderline significance (OR, 1.4, 95 percent CI, 1.0–2.0; p=0.054). Myocardial infarction and stroke, on the other hand, were unaffected by thienopyridine interruptions.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.